Invention Grant
US08420072B2 Vaccination of sex reversed hybrid tilapia (Oreochromis niloticus x O. aureus) with an inactivated Vibrio vulnificus vaccine
有权
用灭活的创伤弧菌疫苗接种性逆转杂交罗非鱼(Oreochromis niloticus x O.aureus)
- Patent Title: Vaccination of sex reversed hybrid tilapia (Oreochromis niloticus x O. aureus) with an inactivated Vibrio vulnificus vaccine
- Patent Title (中): 用灭活的创伤弧菌疫苗接种性逆转杂交罗非鱼(Oreochromis niloticus x O.aureus)
-
Application No.: US13071193Application Date: 2011-03-24
-
Publication No.: US08420072B2Publication Date: 2013-04-16
- Inventor: Craig A. Shoemaker , Benjamin R. LaFentz
- Applicant: Craig A. Shoemaker , Benjamin R. LaFentz
- Applicant Address: US DC Washington
- Assignee: The United States of America, as Represented by the Secretary of Agriculture
- Current Assignee: The United States of America, as Represented by the Secretary of Agriculture
- Current Assignee Address: US DC Washington
- Agent John D. Fado; Evelyn M. Rabin; Gail E. Poulos
- Main IPC: A01N63/00
- IPC: A01N63/00 ; A61K39/02 ; A61K39/00

Abstract:
Vibrio vulnificus can cause infections in aquaculture-raised fish and is considered an opportunistic human pathogen. We isolated V. vulnificus from diseased hybrid tilapia (Oreochromis niloticus X O. aureus) cultured in a North American water reuse aquaculture facility. We have characterized the isolate using biochemical and molecular methods, developed a disease infection model, and determined that formalin-inactivated whole-cell vaccine provides protection against V. vulnificus. The V. vulnificus isolate was determined to be biotype 1, 16S rRNA type B, vcg type C, and vvhA type 2. Fish vaccinated with the formalin-inactivated whole-cell vaccine responded to vaccination as measured by agglutinating antibody titer. In two separate trials, vaccinated tilapia exhibited relative percent survival of 73 and 60% following challenge with the homologous isolate. In additional trials, vaccinated tilapia exhibited survival values of up to 87.5% following challenge with a heterologous isolate. Use of a mineral oil adjuvant enhanced protection.
Public/Granted literature
Information query